Alkain® (Alcaine®)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceProxymethacaineProxymethacaine
Similar drugsTo uncover
  • Alkain®
    drops d / eye 
    ALKON PHARMACEUTICS, LLC     Russia
    • Dosage form: & nbspeye drops
    Composition:

    1 ml of the solution contains:

    active substance: Proxymethacaine hydrochloride 5.0 mg;

    Excipients: benzalkonium chloride, a solution equivalent to benzalkonium chloride 0.1 mg, glycerol 24.5 mg, hydrochloric acid concentrated and / or sodium hydroxide q.s., water purified to 1 ml.

    Description:

    Transparent solution from colorless to slightly yellowish or slightly yellowish-brown in color.

    Pharmacotherapeutic group:local anesthetic
    ATX: & nbsp

    S.01.H.A   Local Anesthetics

    S.01.H.A.04   Proxymethacaine

    Pharmacodynamics:

    Proxymethacaine is a local anesthetic from the group of esters for use in ophthalmology. The action usually develops 30 seconds after instillation and lasts about 15 minutes.

    Proxymethacaine inhibits the permeability of cell membranes for sodium ions, which prevents generation of impulses in nerve endings and impulses along nerve fibers.

    Pharmacokinetics:

    After instillation into the eye, it is rapidly absorbed through the conjunctival capillaries and hydrolyzed by plasma esterases. It is excreted by the kidneys in the form of inactive cleavage products.

    Indications:

    Local anesthesia in ophthalmology for short-term diagnostic and treatment procedures that require fast and short-term anesthesia: surgery to remove cataracts, remove suture filaments from the cornea or conjunctiva; tonometry, gonioscopy; removal of foreign bodies from the cornea; conjunctival scraping for diagnostic purposes.

    Contraindications:

    Hypersensitivity to the components of the drug.

    Carefully:

    Patients with allergic reactions, epilepsy, heart disease, hyperthyroidism and breathing disorders; patients suffering from myasthenia gravis gravis, patients with low acetylcholinesterase in plasma, as well as patients undergoing treatment with cholinesterase inhibitors (because they are more at risk of systemic adverse reactions), children under 18 years of age (since there is not enough experience in using the drug in children).

    Dosing and Administration:

    Locally.

    When performing tonometry and other short-term procedures Bury 1-2 drops immediately before the procedure. If necessary, you can increase the dose.

    For small surgical procedures (removal of the foreign body or removal of the suture thread), 1-2 drops every 5-10 minutes (1-3 times).

    If necessary, prolonged anesthesia (with the removal of cataracts) - 1-2 drops every 5-10 minutes (3-5 times).

    Side effects:

    Local

    In 1-10% of cases: itching, burning eyes, conjunctival hyperemia.

    In 0.1-1% of cases: Immediately after instillation, allergic reactions of immediate type can develop, characterized by the development of epithelial keratitis with the formation of infiltrates and necrosis zones of the epithelium; diffuse stromal edema, descemetitis, iritis.

    System

    In 0.01-0.1% of cases: systemic toxicity, manifested in the excitation of the central nervous system, followed by its inhibition.

    Transient blurred vision, after instillation of the drug; photophobia; increased tear; corneal infection and / or corneal opacity with a prolonged loss of vision and. perforation of the cornea, as a result of increased the applied amount of the drug (the frequency is unknown).

    Overdose:

    If eye contact occurs in excess of the drug, wash your eyes with warm water.

    When developing toxic reactions in case of overdose or hypersensitivity, it is recommended to calm the patient, maintain lung ventilation and breathing by introducing oxygen.

    If seizures occur, intravenous short-acting barbiturates can be administered or diazepam.

    In the case of circulatory failure, intravenous vasopressor drugs are prescribed, such as ephedrine and metameninol.

    Interaction:

    Data on drug interaction are absent.

    Special instructions:

    After surgical manipulation it is necessary to cover up, eye bandage, tk. The blinking reflex is temporarily eliminated.

    The drug Alkain® can be used only for topical application in ophthalmology and is not intended for injection.

    It is not recommended to use contact lenses when using the drug Alkain®.

    Prolonged use of the drug Alkain® can reduce the duration of the effect and require an increase in the amount of the drug necessary to achieve the desired anesthetic effect.

    During the entire period of anesthesia, it is necessary to protect the eye from getting into it irritants, foreign bodies, and also do not rub the eye until the action of the anesthetic passes.

    When developing symptoms of hypersensitivity or eye irritation, stop using the drug.

    The bottle must be closed after each use.

    Do not touch the tip of the pipette to the eye.

    Effect on the ability to drive transp. cf. and fur:

    If, after the application of the drug, a brief blurring of vision has occurred, it is not recommended to drive vehicles and engage in activities requiring increased attention and reaction, before recovery.

    Form release / dosage:

    Eye drops, 0,5%.

    Packaging:

    For 15 ml in the bottle-drip "Droptainer ™" from low-density polyethylene.

    For 1 bottle with instructions for use in a pack of cardboard.

    Storage conditions:

    At a temperature of 2 to 8 ° C in the refrigerator, out of the reach of children.

    Shelf life:

    30 months.

    After opening the vial, the drug should be used within 4 weeks.

    Do not use after the expiry date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:П N012071 / 01
    Date of registration:06.08.2010
    The owner of the registration certificate:ALKON PHARMACEUTICS, LLC ALKON PHARMACEUTICS, LLC Russia
    Manufacturer: & nbsp
    Representation: & nbspALKON PHARMACEUTICS LLCALKON PHARMACEUTICS LLCRussia
    Information update date: & nbsp04.09.2015
    Illustrated instructions
      Instructions
      Up